Druggability & Clinical Context
Druggability
Undruggable
Score: 0.20
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
2 Preclinical
Therapeutic Areas:Neurodegenerative diseases (Alzheimer's, Parkinson's) Neuroinflammation and CNS disorders Blood-brain barrier dysfunction Stroke and cerebral ischemia Brain tumor drug delivery enhancement Neurotrauma and traumatic brain injury
Druggability Rationale: Despite CLDN5's critical role in blood-brain barrier integrity and neurological disease pathogenesis, it remains a challenging druggability target due to limited established pharmacological intervention mechanisms. While preclinical anti-CLDN5 antibodies and size-selective BBB modulators show potential promise, the lack of clear structure-based drug design strategies and the protein's complex tight junction functional role currently constrains direct therapeutic targeting. Further structural and mechanistic research is needed to develop precise molecular strategies for modulating CLDN5's function in neurodegeneration.
Mechanism: Tight junction protein modulation - no established druggable mechanisms
Drug Pipeline (2 compounds)
2 Preclinical
Known Drugs:Anti-CLDN5 antibodies (preclinical) — Transient BBB opening for drug delivery
Size-selective BBB modulators (preclinical) — Claudin-5 targeted siRNA for BBB modulation
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:CLDN5 lacks identified druggable small-molecule binding pockets; instead, therapeutic engagement occurs through antibody epitopes on extracellular loops or indirect modulation via partner proteins (occludin, ZO-1). The target is best approached through biologics or allosteric modulators affecting claudin-claudin interactions rather than orthosteric small-molecule binding at a defined active site.
Selectivity & Safety Considerations
Selectivity is a critical challenge given CLDN5's widespread expression across multiple claudin family members (CLDN1-24) and its tissue distribution beyond the BBB in other tight junction barriers. Off-target disruption of gastrointestinal, renal, or skin barrier function poses significant safety liabilities; any therapeutic approach requires BBB-specific targeting strategies to minimize systemic claudin modulation.
Clinical Trials (5)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 3 · PHASE4: 1 · Unknown: 1
NA
NCT07361887
n=8
Atherosclerosis Cardiovascular Disease, Obesity, Metabolic Syndrome
Interventions: White Wine, Red Wine, Water
Sponsor: University of Seville
NA
NCT04529265
n=314
Postoperative Delirium
Interventions: Methylene Blue, Placebo
Sponsor: Fudan University
Unknown
NCT05450822
n=550
Epilepsy
Interventions: Levetiracetam, Levetiracetam Tablets, Lamotrigine tablet
Sponsor: Gitte Moos Knudsen
PHASE4
NCT06078215
n=350
Acute Ischemic Stroke
Interventions: Cerebrolysin
Sponsor: Poznan University of Medical Sciences
NA
NCT05192447
n=150
Brain Tumors, Radiotherapy
Interventions: Exercise treatment
Sponsor: The Greater Poland Cancer Centre